Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.
Jacobson P.B., Goody R., Lawrence M., Mueller B.K., Zhang X., Hooker B.A., Pfleeger K., Ziemann A., Locke C., Barraud Q. et al., 2021/07. Neurobiology of disease, 155 p. 105385. Peer-reviewed.
ici le détail